Ann: Orthocell commences nerve repair study, page-4

End of April Appendix 4C coming soon and hopefully more Striate insight.

I am surprised people still selling this stock. We know its a shoo-in for FDA approval on this, its been discussed to death with them (for too long) - this proof has been executed before against sutures in this style, now against a comparator too. Then again, I never thought it would trade below $0.40 again after the Bio Horizons deal, so what do I know?

Now they have Striate deal, if they do another partnership deal on Remplir, you know its going to be on very favourable terms. The results for Henry Schein in Striate were compelling. We've all seen the human results, qaudriplegic grafts particularly, are even more compelling in this, than this low FDA hurdle of animal studies, similar of which they excelled in before, with 30% improved sensory function over traditional methods in very early animal studies (I am sure they've improved application since).

We know as the notice informs us, in its 07 June 2022 clinical data, OCC demonstrated that nerve repair with Remplir following injury to the spinal cord, brachial plexus and other nerves of the upper limbs consistently restores arm and hand function to previously paralysed limbs.....functional recovery of muscles controlled by the repaired nerve was observed in 85% (23 of 27) of nerve repairs at 24 months post-treatment.

Now lets be naughty, and have a look at an anecdotal case of the rock climber with an injured hand nerve they treated, post treatment: